{"id":"non-steroidal-aromatase-inhibitor-therapy","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hot flashes"},{"rate":"15-25","effect":"Arthralgia/joint pain"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Vaginal dryness"},{"rate":null,"effect":"Osteoporosis/bone loss"},{"rate":null,"effect":"Elevated cholesterol"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aromatase inhibitors (AIs) work by inhibiting the aromatase enzyme, which converts androgens to estrogen in postmenopausal women. By reducing circulating estrogen levels, these agents deprive estrogen receptor-positive breast cancer cells of the hormonal stimulus needed for growth and proliferation. Non-steroidal AIs are reversible competitive inhibitors of aromatase, distinguishing them from steroidal AIs.","oneSentence":"A non-steroidal aromatase inhibitor blocks the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:21.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic setting)"}]},"trialDetails":[{"nctId":"NCT02712723","phase":"PHASE2","title":"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qamar Khan","startDate":"2016-02","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT05501886","phase":"PHASE3","title":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celcuity Inc","startDate":"2022-12-08","conditions":"Breast Cancer","enrollment":701},{"nctId":"NCT07366632","phase":"PHASE1","title":"A Study of Single Dose of BL0175 in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-01-26","conditions":"Postmenopausal Women","enrollment":27},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT03822468","phase":"PHASE2","title":"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-11","conditions":"Breast Cancer","enrollment":376},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":"Breast Neoplasm Female","enrollment":1050},{"nctId":"NCT07072013","phase":"","title":"An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-08","conditions":"Breast Cancer","enrollment":1937},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT05190094","phase":"PHASE2","title":"Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.","status":"RECRUITING","sponsor":"International Cancer Research Group, United Arab Emirates","startDate":"2022-12-20","conditions":"Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer","enrollment":80},{"nctId":"NCT04321551","phase":"PHASE4","title":"Hormone Secretion in Transgender Males","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2023-07-01","conditions":"Transgender, Healthy","enrollment":""},{"nctId":"NCT03227328","phase":"PHASE2","title":"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-08-02","conditions":"Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer","enrollment":52},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT02028507","phase":"PHASE3","title":"Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2014-03-13","conditions":"Metastatic Breast Cancer","enrollment":693},{"nctId":"NCT03870919","phase":"NA","title":"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2019-10-23","conditions":"Breast Cancer Stage IV, Radiotherapy, Surgery","enrollment":200},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT02730923","phase":"PHASE1, PHASE2","title":"Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)","status":"UNKNOWN","sponsor":"Centre Leon Berard","startDate":"2016-04","conditions":"Endometrial Carcinoma, Metastatic Carcinoma, Hormone Receptor Positive Tumor","enrollment":72},{"nctId":"NCT04869943","phase":"PHASE3","title":"Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2021-10-12","conditions":"Metastatic Breast Cancer","enrollment":52},{"nctId":"NCT03312738","phase":"PHASE2","title":"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-15","conditions":"Advanced Breast Cancer","enrollment":159},{"nctId":"NCT04707196","phase":"PHASE4","title":"A Study of Abemaciclib in Indian Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":200},{"nctId":"NCT02585388","phase":"PHASE2","title":"Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.","status":"TERMINATED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2015-10-23","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00556374","phase":"PHASE3","title":"Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-18","conditions":"Breast Cancer","enrollment":3420},{"nctId":"NCT05079360","phase":"PHASE2","title":"Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Veru Inc.","startDate":"2023-03-15","conditions":"Metastatic Breast Cancer","enrollment":""},{"nctId":"NCT02753686","phase":"","title":"Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-03-15","conditions":"HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer","enrollment":440},{"nctId":"NCT05569187","phase":"","title":"Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-03-23","conditions":"Breast Cancer","enrollment":76},{"nctId":"NCT02444390","phase":"NA","title":"Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-05-19","conditions":"Metastatic Breast Cancer","enrollment":150},{"nctId":"NCT00676663","phase":"PHASE2","title":"Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Syndax Pharmaceuticals","startDate":"2008-06-13","conditions":"Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive","enrollment":130},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00186121","phase":"PHASE2","title":"Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women","status":"COMPLETED","sponsor":"Stanford University","startDate":"2000-10","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT02765373","phase":"","title":"Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-01","conditions":"Breast Cancer","enrollment":500},{"nctId":"NCT01978171","phase":"","title":"Prediction of Everolimus-induced Interstitial Lung Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-05","conditions":"Breast Neoplasms","enrollment":27},{"nctId":"NCT01626222","phase":"PHASE3","title":"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Metastatic Breast Cancer","enrollment":301},{"nctId":"NCT00814034","phase":"","title":"Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy","status":"COMPLETED","sponsor":"Hellenic Breast Surgeons Society","startDate":"2008-02","conditions":"Breast Cancer","enrollment":306},{"nctId":"NCT01368263","phase":"PHASE2","title":"Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2011-09","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer","enrollment":8},{"nctId":"NCT00065325","phase":"PHASE3","title":"The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-08","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":694},{"nctId":"NCT00066339","phase":"PHASE2","title":"Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-05","conditions":"Breast Cancer","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Non-steroidal aromatase inhibitor therapy","genericName":"Non-steroidal aromatase inhibitor therapy","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A non-steroidal aromatase inhibitor blocks the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}